Reshape Lifesciences Stock Last Dividend Paid

RSLS Stock

USD 5.68 0.07 1.22%

ReShape Lifesciences fundamentals help investors to digest information that contributes to ReShape Lifesciences' financial success or failures. It also enables traders to predict the movement of ReShape Stock. The fundamental analysis module provides a way to measure ReShape Lifesciences' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to ReShape Lifesciences stock.

Total Liab Other Stockholder Equity

This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

ReShape Lifesciences Company Last Dividend Paid Analysis

ReShape Lifesciences' Last Dividend Paid refers to dividend per share(DPS) paid to the shareholder the last time dividends were issued by a company. In its conventional sense, dividends refer to the distribution of some of a company's net earnings or capital gains decided by the board of directors.

Last Dividend

Last Profit Distribution Amount

Total Shares

More About Last Dividend Paid | All Equity Analysis

ReShape Last Dividend Paid Driver Correlations

Understanding the fundamental principles of building solid financial models for ReShape Lifesciences is extremely important. It helps to project a fair market value of ReShape Stock properly, considering its historical fundamentals such as Last Dividend Paid. Since ReShape Lifesciences' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of ReShape Lifesciences' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of ReShape Lifesciences' interrelated accounts and indicators.

	Total Assets	Total Stockholder Equity	Retained Earnings	Total Liab	Net Debt	Accounts Payable	Long Term Debt	Net Receivables	Total Current Assets	Short Term Debt	Common Stock	Property Plant Equipment	Short Term Investments	Current Deferred Revenue	Net Tangible Assets	Long Term Debt Total	Capital Surpluse	Short Long Term Debt	Net Invested Capital	Net Working Capital	Capital Stock
Total Assets		0.97	-0.13	0.57	-0.3	0.34	-0.18	0.25	0.26	0.23	0.12	0.07	0.37	0.31	-0.09	0.0	0.28	0.31	0.08	0.13	0.01
Total Stockholder Equity	0.97		-0.13	0.37	-0.32	0.27	-0.19	0.19	0.26	0.18	0.09	0.14	0.47	0.28	0.04	0.01	0.27	0.31	0.12	0.27	0.05
Retained Earnings	-0.13	-0.13		-0.08	-0.22	-0.69	-0.5	-0.73	0.19	0.28	0.51	-0.27	0.31	-0.58	0.4	-0.75	-0.91	-0.4	0.88	0.05	0.85
Total Liab	0.57	0.37	-0.08		-0.07	0.42	-0.02	0.35	0.11	0.26	0.16	-0.22	-0.18	0.22	-0.49	-0.06	0.19	0.15	-0.1	-0.45	-0.13
Net Debt	-0.3	-0.32	-0.22	-0.07		0.2	0.06	0.19	-0.95	0.07	-0.5	-0.59	0.16	0.14	-0.71	0.13	0.32	0.11	-0.45	-0.69	-0.21
Accounts Payable	0.34	0.27	-0.69	0.42	0.2		0.39	0.96	-0.18	-0.3	-0.57	0.16	-0.18	0.49	-0.36	0.46	0.8	0.52	-0.65	-0.11	-0.81
Long Term Debt	-0.18	-0.19	-0.5	-0.02	0.06	0.39		0.45	0.12	-0.31	-0.49	0.6	-0.22	0.17	0.1	0.82	0.47	0.32	-0.68	0.07	-0.66
Net Receivables	0.25	0.19	-0.73	0.35	0.19	0.96	0.45		-0.14	-0.37	-0.55	0.2	-0.2	0.43	-0.32	0.47	0.83	0.46	-0.72	-0.12	-0.89
Total Current Assets	0.26	0.26	0.19	0.11	-0.95	-0.18	0.12	-0.14		0.01	0.45	0.57	-0.24	-0.15	0.71	-0.02	-0.32	-0.08	0.32	0.61	0.14
Short Term Debt	0.23	0.18	0.28	0.26	0.07	-0.3	-0.31	-0.37	0.01		0.34	-0.39	-0.13	-0.15	-0.15	-0.37	-0.23	0.03	0.24	-0.18	0.57
Common Stock	0.12	0.09	0.51	0.16	-0.5	-0.57	-0.49	-0.55	0.45	0.34		-0.07	-0.17	-0.55	0.2	-0.55	-0.57	-0.15	0.6	0.1	0.58
Property Plant Equipment	0.07	0.14	-0.27	-0.22	-0.59	0.16	0.6	0.2	0.57	-0.39	-0.07		-0.08	0.01	0.64	0.49	0.23	0.17	-0.12	0.76	-0.34
Short Term Investments	0.37	0.47	0.31	-0.18	0.16	-0.18	-0.22	-0.2	-0.24	-0.13	-0.17	-0.08		-0.06	0.1	-0.18	-0.1	-0.12	0.31	0.05	0.28
Current Deferred Revenue	0.31	0.28	-0.58	0.22	0.14	0.49	0.17	0.43	-0.15	-0.15	-0.55	0.01	-0.06		-0.26	0.55	0.52	0.21	-0.44	-0.07	-0.41
Net Tangible Assets	-0.09	0.04	0.4	-0.49	-0.71	-0.36	0.1	-0.32	0.71	-0.15	0.2	0.64	0.1	-0.26		-0.09	-0.45	-0.14	0.48	0.81	0.28
Long Term Debt Total	0.0	0.01	-0.75	-0.06	0.13	0.46	0.82	0.47	-0.02	-0.37	-0.55	0.49	-0.18	0.55	-0.09		0.65	0.46	-0.76	0.08	-0.71
Capital Surpluse	0.28	0.27	-0.91	0.19	0.32	0.8	0.47	0.83	-0.32	-0.23	-0.57	0.23	-0.1	0.52	-0.45	0.65		0.56	-0.83	-0.11	-0.81
Short Long Term Debt	0.31	0.31	-0.4	0.15	0.11	0.52	0.32	0.46	-0.08	0.03	-0.15	0.17	-0.12	0.21	-0.14	0.46	0.56		-0.42	-0.08	-0.39
Net Invested Capital	0.08	0.12	0.88	-0.1	-0.45	-0.65	-0.68	-0.72	0.32	0.24	0.6	-0.12	0.31	-0.44	0.48	-0.76	-0.83	-0.42		0.34	0.88
Net Working Capital	0.13	0.27	0.05	-0.45	-0.69	-0.11	0.07	-0.12	0.61	-0.18	0.1	0.76	0.05	-0.07	0.81	0.08	-0.11	-0.08	0.34		0.12
Capital Stock	0.01	0.05	0.85	-0.13	-0.21	-0.81	-0.66	-0.89	0.14	0.57	0.58	-0.34	0.28	-0.41	0.28	-0.71	-0.81	-0.39	0.88	0.12

Click cells to compare fundamentals

Many stable companies today pay out dividends to their shareholders in the form of the income distribution, but high-growth firms rarely offer dividends because all of their earnings are reinvested back to the business.

Competition

Predict ReShape Lifesciences

Based on the recorded statements, ReShape Lifesciences has a Last Dividend Paid of 0.0. This indicator is about the same for the Health Care Equipment & Supplies average (which is currently at 0.0) sector and about the same as Health Care (which currently averages 0.0) industry. This indicator is about the same for all United States stocks average (which is currently at 0.0).

ReShape Lifesciences Current Valuation Drivers

We derive many important indicators used in calculating different scores of ReShape Lifesciences from analyzing ReShape Lifesciences' financial statements. These drivers represent accounts that assess ReShape Lifesciences' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of ReShape Lifesciences' important valuation drivers and their relationship over time.

	2019	2020	2021	2022	2023	2024 (projected)
Market Cap	26.8M	17.6M	17.9M	2.9M	1.5M	1.4M
Enterprise Value	24.7M	15.1M	(4.6M)	(823.6K)	(2.7M)	(2.6M)

ReShape Lifesciences ESG Sustainability

Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, ReShape Lifesciences' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to ReShape Lifesciences' managers, analysts, and investors.

Environmental

Governance

Social

ReShape Fundamentals

	Return On Equity	-1.85
	Return On Asset	-0.63
	Profit Margin	(1.12) %
	Operating Margin	(1.05) %
	Current Valuation	3.4 M
	Shares Outstanding	712.68 K
	Shares Owned By Insiders	5.57 %
	Shares Owned By Institutions	1.83 %
	Number Of Shares Shorted	25.01 K
	Price To Book	2.66 X
	Price To Sales	0.51 X
	Revenue	8.68 M
	Gross Profit	6.8 M
	EBITDA	(14.48 M)
	Net Income	(11.39 M)
	Cash And Equivalents	11.49 M
	Cash Per Share	0.51 X
	Total Debt	262 K
	Debt To Equity	0.01 %
	Current Ratio	2.12 X
	Book Value Per Share	16.48 X
	Cash Flow From Operations	(16.96 M)
	Short Ratio	0.22 X
	Earnings Per Share	76.20 X
	Price To Earnings To Growth	(12.12) X
	Target Price	1.0
	Number Of Employees	29
	Beta	1.35
	Market Capitalization	3.64 M
	Total Asset	10.66 M
	Retained Earnings	(635.57 M)
	Working Capital	6.52 M
	Net Asset	10.66 M

About ReShape Lifesciences Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze ReShape Lifesciences's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of ReShape Lifesciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of ReShape Lifesciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for ReShape Stock Analysis

When running ReShape Lifesciences' price analysis, check to measure ReShape Lifesciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ReShape Lifesciences is operating at the current time. Most of ReShape Lifesciences' value examination focuses on studying past and present price action to predict the probability of ReShape Lifesciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ReShape Lifesciences' price. Additionally, you may evaluate how the addition of ReShape Lifesciences to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC